趋化因子CCL2作为前列腺癌潜在生物标志物的初步研究
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
作者信息
Tsaur Igor, Noack Anika, Makarevic Jasmina, Oppermann Elsie, Waaga-Gasser Ana Maria, Gasser Martin, Borgmann Hendrik, Huesch Tanja, Gust Kilian M, Reiter Michael, Schilling David, Bartsch Georg, Haferkamp Axel, Blaheta Roman A
机构信息
Department of Urology and Pediatric Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Department of Surgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
出版信息
Cancer Res Treat. 2015 Apr;47(2):306-12. doi: 10.4143/crt.2014.015. Epub 2014 Oct 13.
PURPOSE
Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa.
MATERIALS AND METHODS
Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested.
RESULTS
The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading.
CONCLUSION
Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.
目的
前列腺特异性抗原在诊断前列腺癌（PCa）方面并不可靠，因此鉴定新的、精确的诊断生物标志物具有重要意义。由于趋化因子与多种恶性肿瘤中更具侵袭性的疾病和不良预后相关，我们旨在研究趋化因子在PCa中的诊断相关性。
材料与方法
从39例连续接受根治性前列腺切除术的PCa患者中获取术前和术后早期血清样本。15名健康志愿者的血清作为对照。通过Luminex检测血清中CXCL12、CXCL13、CX3CL1、CCL2、CCL5和CCL20的浓度。通过定量实时聚合酶链反应评估前列腺切除标本的肿瘤组织和相邻正常组织中CXCR3、CXCR4、CXCR5、CXCR7、CXCL12、CXCL13、CX3CR1、CXCL1、CCR2、CCR5、CCR6、CCR7、CCL2和CCL5 mRNA的表达活性。测试这些趋化因子与临床和组织学参数的相关性。
结果
与相邻正常组织相比，肿瘤组织中CCL2和CCR6的基因表达活性显著更高。与对照组相比，PCa患者血样中的CCL2也显著更高。与对照组相比，患者血清中的CCL5、CCL20和CX3CL1较低。CCR2组织mRNA与Gleason评分和分级呈负相关。
结论
趋化因子在PCa肿瘤发生过程中发生显著改变，CCL2是一种有前景的诊断生物标志物。
Zotero 插件